{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:53:50Z","timestamp":1761630830693,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.arbres.2018.04.004","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T23:44:53Z","timestamp":1529711093000},"page":"510-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u00bfC\u00f3mo realizamos el cribado de infecci\u00f3n tuberculosa latente en pacientes candidatos a terapias biol\u00f3gicas en Espa\u00f1a? Una encuesta multidisciplinar"],"prefix":"10.1016","volume":"54","author":[{"given":"Sarai","family":"Quir\u00f3s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"de la Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ane","family":"Uranga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Madero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanel","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Bruguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia A.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Iturbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Lera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Luque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abel J.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"M\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Su\u00e1rez-Cuart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2018.04.004_bib0145","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2018.04.004_bib0150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.arbres.2018.04.004_bib0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.arbres.2011.01.013","article-title":"New challenges for the pulmonologist in the diagnosis of latent tuberculosis infection: biological treatment and pulmonary tuberculosis","volume":"47","author":"Hern\u00e1ndez Gonz\u00e1lez","year":"2011","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.arbres.2018.04.004_bib0160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.berh.2011.06.001","article-title":"Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-\u03b1) era","volume":"25","author":"Nacci","year":"2011","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"10.1016\/j.arbres.2018.04.004_bib0165","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2018.04.004_bib0170","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.arbres.2018.04.004_bib0175","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.arbres.2018.04.004_bib0180","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.arbres.2018.04.004_bib0185","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.arbres.2018.04.004_bib0190","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.22504","article-title":"Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists","volume":"56","author":"Curtis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.arbres.2018.04.004_bib0195","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.arbres.2018.04.004_bib0200","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol."},{"key":"10.1016\/j.arbres.2018.04.004_bib0205","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ibd.20496","article-title":"Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti -TNF therapy","volume":"14","author":"Zabana","year":"2008","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.arbres.2018.04.004_bib0210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.arbres.2018.04.004_bib0215","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.arbres.2018.04.004_bib0220","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arbres.2015.04.016","article-title":"Documento de consenso sobre la prevenci\u00f3n y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol\u00f3gico","volume":"52","author":"Mir Viladrich","year":"2016","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.arbres.2018.04.004_bib0225","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/jdv.12011","article-title":"Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain BIOBADADERM registry","volume":"27","author":"S\u00e1nchez-Moya","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.arbres.2018.04.004_bib0230","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.arbres.2008.05.008","article-title":"Est\u00e1ndares de calidad asistencial en la EPOC","volume":"45","author":"Soler Catalu\u00f1a","year":"2009","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.arbres.2018.04.004_bib0235","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and posmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.arbres.2018.04.004_bib0240","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.21382","article-title":"Tuberculosis associated with therapy against tumor necrosis factor alpha","volume":"52","author":"Winthrop","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.arbres.2018.04.004_bib0245","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon-\u03b3 release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"64","author":"Hsia","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.arbres.2018.04.004_bib0250","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez Reino","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.arbres.2018.04.004_bib0255","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.eimc.2012.06.014","article-title":"Use of Quantiferon-TB-Gold in Tube\u00ae test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice","volume":"31","author":"Garc\u00eda Gasalla","year":"2013","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.arbres.2018.04.004_bib0260","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","article-title":"Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis","volume":"64","author":"Ponce de Leon","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.arbres.2018.04.004_bib0265","first-page":"776","article-title":"Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population","volume":"35","author":"Ponce de Leon","year":"2008","journal-title":"J Rheumatol."},{"key":"10.1016\/j.arbres.2018.04.004_bib0270","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/annrheumdis-2011-200941","article-title":"Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-\u03b3 release assays under real-life conditions","volume":"71","author":"Kleinert","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.arbres.2018.04.004_bib0275","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","article-title":"Influence of replacing tuberculin skin test with ex vivo interferon \u03b3 release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy","volume":"71","author":"Mariette","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.arbres.2018.04.004_bib0280","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","article-title":"The tuberculin skin test","volume":"17","author":"Huebner","year":"1993","journal-title":"Clin Infect Dis."}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030028961830156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030028961830156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:37:03Z","timestamp":1759531023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030028961830156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S030028961830156X"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2018.04.004","relation":{},"ISSN":["0300-2896"],"issn-type":[{"type":"print","value":"0300-2896"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00bfC\u00f3mo realizamos el cribado de infecci\u00f3n tuberculosa latente en pacientes candidatos a terapias biol\u00f3gicas en Espa\u00f1a? Una encuesta multidisciplinar","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2018.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}